Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]R. Siegel, D. Naishadham and A. Jemal: Cancer statistics, 2013. CA Cancer J Clin, 63(1), 11-30 (2013)

  • [2]S. J. Freedland, E. B. Humphreys, L. A. Mangold, M. Eisenberger, F. J. Dorey, P. C. Walsh and A. W. Partin: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA, 294(4), 433-439 (2005)

  • [3]A. Heidenreich, P. J. Bastian, J. Bellmunt, M. Bolla, S. Joniau, T. van der Kwast, M. Mason, V. Matveev, T. Wiegel, F. Zattoni and N. Mottet: EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol, 65(1), 124-137 (2014)

  • [4]I. Thompson, J. B. Thrasher, G. Aus, A. L. Burnett, E. D. Canby-Hagino, M. S. Cookson, A. V. D’Amico, R. R. Dmochowski, D. T. Eton, J. D. Forman, S. L. Goldenberg, J. Hernandez, C. S. Higano, S. R. Kraus, J. W. Moul and C. M. Tangen: Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol, 177(6), 2106-2131 (2007)

  • [5]A. V. D’Amico, R. Whittington, S. B. Malkowicz, D. Schultz, K. Blank, G. A. Broderick, J. E. Tomaszewski, A. A. Renshaw, I. Kaplan, C. J. Beard and A. Wein: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280(11), 969-974 (1998)

  • [6]S. L. Conti, M. Dall’era, V. Fradet, J. E. Cowan, J. Simko and P. R. Carroll: Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol, 181(4), 1628-1633; discussion 1633-1624 (2009)

  • [7]M. Muntener, J. I. Epstein, D. J. Hernandez, M. L. Gonzalgo, L. Mangold, E. Humphreys, P. C. Walsh, A. W. Partin and M. E. Nielsen: Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol, 53(4), 767-775; discussion 775-766 (2008)

  • [8]S. A. Tomlins, R. Mehra, D. R. Rhodes, X. Cao, L. Wang, S. M. Dhanasekaran, S. Kalyana-Sundaram, J. T. Wei, M. A. Rubin, K. J. Pienta, R. B. Shah and A. M. Chinnaiyan: Integrative molecular concept modeling of prostate cancer progression. Nat Genet, 39(1), 41-51 (2007)

  • [9]D. V. Makarov, S. Loeb, R. H. Getzenberg and A. W. Partin: Biomarkers for prostate cancer. Annu Rev Med, 60, 139-151 (2009)

  • [10]D. Singh, P. G. Febbo, K. Ross, D. G. Jackson, J. Manola, C. Ladd, P. Tamayo, A. A. Renshaw, A. V. D’Amico, J. P. Richie, E. S. Lander, M. Loda, P. W. Kantoff, T. R. Golub and W. R. Sellers: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell, 1(2), 203-209 (2002)

  • [11]J. C. Cheville, R. J. Karnes, T. M. Therneau, F. Kosari, J. M. Munz, L. Tillmans, E. Basal, L. J. Rangel, E. Bergstralh, I. V. Kovtun, C. D. Savci-Heijink, E. W. Klee and G. Vasmatzis: Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol, 26(24), 3930-3936 (2008)

  • [12]J. Cuzick, D. M. Berney, G. Fisher, D. Mesher, H. Moller, J. E. Reid, M. Perry, J. Park, A. Younus, A. Gutin, C. S. Foster, P. Scardino, J. S. Lanchbury and S. Stone: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer, 106(6), 1095-1099 (2012)

  • [13]Z. Ding, C. J. Wu, G. C. Chu, Y. Xiao, D. Ho, J. Zhang, S. R. Perry, E. S. Labrot, X. Wu, R. Lis, Y. Hoshida, D. Hiller, B. Hu, S. Jiang, H. Zheng, A. H. Stegh, K. L. Scott, S. Signoretti, N. Bardeesy, Y. A. Wang, D. E. Hill, T. R. Golub, M. J. Stampfer, W. H. Wong, M. Loda, L. Mucci, L. Chin and R. A. DePinho: SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature, 470(7333), 269-273 (2011)

  • [14]A. E. Ross, F. Y. Feng, M. Ghadessi, N. Erho, A. Crisan, C. Buerki, D. Sundi, A. P. Mitra, I. A. Vergara, D. J. Thompson, T. J. Triche, E. Davicioni, E. J. Bergstralh, R. B. Jenkins, R. J. Karnes and E. M. Schaeffer: A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis, 17(1), 64-69 (2014)

  • [15]S. Irshad, M. Bansal, M. Castillo-Martin, T. Zheng, A. Aytes, S. Wenske, C. Le Magnen, P. Guarnieri, P. Sumazin, M. C. Benson, M. M. Shen, A. Califano and C. Abate-Shen: A molecular signature predictive of indolent prostate cancer. Sci Transl Med, 5(202), 202ra122 (2013)

  • [16]A. Tradonsky, T. Rubin, R. Beck, B. Ring, R. Seitz and S. Mair: A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol, 137(6), 918-930 (2012)

  • [17]R. J. Karnes, E. J. Bergstralh, E. Davicioni, M. Ghadessi, C. Buerki, A. P. Mitra, A. Crisan, N. Erho, I. A. Vergara, L. L. Lam, R. Carlson, D. J. Thompson, Z. Haddad, B. Zimmermann, T. Sierocinski, T. J. Triche, T. Kollmeyer, K. V. Ballman, P. C. Black, G. G. Klee and R. B. Jenkins: Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol, 190(6), 2047-2053 (2013)

  • [18]F. Crea, A. Watahiki, L. Quagliata, H. Xue, L. Pikor, A. Parolia, Y. Wang, D. Lin, W. L. Lam, W. L. Farrar, T. Isogai, R. Morant, S. Castori-Eppenberger, K. N. Chi and C. D. Helgason: Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget, 5(3), 764-774 (2014)

  • [19]S. Varambally, S. M. Dhanasekaran, M. Zhou, T. R. Barrette, C. Kumar-Sinha, M. G. Sanda, D. Ghosh, K. J. Pienta, R. G. Sewalt, A. P. Otte, M. A. Rubin and A. M. Chinnaiyan: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419(6907), 624-629 (2002)

  • [20]D. R. Rhodes, M. G. Sanda, A. P. Otte, A. M. Chinnaiyan and M. A. Rubin: Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst, 95(9), 661-668 (2003)

  • [21]S. Lehrer, E. J. Diamond, S. Stagger, N. N. Stone and R. G. Stock: Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate, 50(1), 1-3 (2002)

  • [22]L. F. Pemberton and B. M. Paschal: Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic, 6(3), 187-198 (2005)

  • [23]T. R. Kau, J. C. Way and P. A. Silver: Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer, 4(2), 106-117 (2004)

  • [24]P. Stawerski, M. Wagrowska-Danilewicz, O. Stasikowska and M. Danilewicz: Immunoexpression of CAS protein is augmented in high grade serous ovarian tumors. Pol J Pathol, 61(4), 219-223 (2010)

  • [25]C. C. Chang, C. J. Tai, T. C. Su, K. H. Shen, S. H. Lin, C. M. Yeh, K. T. Yeh, Y. M. Lin and M. C. Jiang: The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas. Ann Diagn Pathol, 16(5), 362-368 (2012)

  • [26]X. T. Liang, K. Pan, M. S. Chen, J. J. Li, H. Wang, J. J. Zhao, J. C. Sun, Y. B. Chen, H. Q. Ma, Q. J. Wang and J. C. Xia: Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol, 26(3), 544-549 (2011)

  • [27]Z. Guo, H. Wang, Y. Li, B. Li, C. Li and C. Ding: A microRNA-related single nucleotide polymorphism of the gene is associated with survival of small cell lung cancer patients. Biomed Rep, 1(4), 545-548 (2013)

  • [28]K. Y. Caceres-Gorriti, E. Carmona, V. Barres, K. Rahimi, I. J. Letourneau, P. N. Tonin, D. Provencher and A. M. Mes-Masson: RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer. PLoS One, 9(3), e91000 (2014)

  • [29]A. Shen, Y. Wang, Y. Zhao, L. Zou, L. Sun and C. Cheng: Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery, 65(1), 153-159; discussion 159-160 (2009)

  • [30]Y. Yao, Y. Dong, F. Lin, H. Zhao, Z. Shen, P. Chen, Y. J. Sun, L. N. Tang and S. E. Zheng: The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep, 21(1), 229-235 (2009)

  • [31]A. Noske, W. Weichert, S. Niesporek, A. Roske, A. C. Buckendahl, I. Koch, J. Sehouli, M. Dietel and C. Denkert: Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer, 112(8), 1733-1743 (2008)

  • [32]W. Y. Huang, L. Yue, W. S. Qiu, L. W. Wang, X. H. Zhou and Y. J. Sun: Prognostic value of CRM1 in pancreas cancer. Clin Invest Med, 32(6), E315 (2009)

  • [33]J. B. Welsh, L. M. Sapinoso, A. I. Su, S. G. Kern, J. Wang-Rodriguez, C. A. Moskaluk, H. F. Frierson, Jr. and G. M. Hampton: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res, 61(16), 5974-5978 (2001)

  • [34]E. LaTulippe, J. Satagopan, A. Smith, H. Scher, P. Scardino, V. Reuter and W. L. Gerald: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res, 62(15), 4499-4506 (2002)

  • [35]J. A. Magee, T. Araki, S. Patil, T. Ehrig, L. True, P. A. Humphrey, W. J. Catalona, M. A. Watson and J. Milbrandt: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res, 61(15), 5692-5696 (2001)

  • [36]Y. P. Yu, D. Landsittel, L. Jing, J. Nelson, B. Ren, L. Liu, C. McDonald, R. Thomas, R. Dhir, S. Finkelstein, G. Michalopoulos, M. Becich and J. H. Luo: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol, 22(14), 2790-2799 (2004)

  • [37]J. Holzbeierlein, P. Lal, E. LaTulippe, A. Smith, J. Satagopan, L. Zhang, C. Ryan, S. Smith, H. Scher, P. Scardino, V. Reuter and W. L. Gerald: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol, 164(1), 217-227 (2004)

  • [38]J. H. Luo, Y. P. Yu, K. Cieply, F. Lin, P. Deflavia, R. Dhir, S. Finkelstein, G. Michalopoulos and M. Becich: Gene expression analysis of prostate cancers. Mol Carcinog, 33(1), 25-35 (2002)

  • [39]J. Lapointe, C. Li, J. P. Higgins, M. van de Rijn, E. Bair, K. Montgomery, M. Ferrari, L. Egevad, W. Rayford, U. Bergerheim, P. Ekman, A. M. DeMarzo, R. Tibshirani, D. Botstein, P. O. Brown, J. D. Brooks and J. R. Pollack: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A, 101(3), 811-816 (2004)

  • [40]M. S. Arredouani, B. Lu, M. Bhasin, M. Eljanne, W. Yue, J. M. Mosquera, G. J. Bubley, V. Li, M. A. Rubin, T. A. Libermann and M. G. Sanda: Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res, 15(18), 5794-5802 (2009)

  • [41]S. Varambally, J. Yu, B. Laxman, D. R. Rhodes, R. Mehra, S. A. Tomlins, R. B. Shah, U. Chandran, F. A. Monzon, M. J. Becich, J. T. Wei, K. J. Pienta, D. Ghosh, M. A. Rubin and A. M. Chinnaiyan: Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 8(5), 393-406 (2005)

  • [42]B. S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B. S. Carver, V. K. Arora, P. Kaushik, E. Cerami, B. Reva, Y. Antipin, N. Mitsiades, T. Landers, I. Dolgalev, J. E. Major, M. Wilson, N. D. Socci, A. E. Lash, A. Heguy, J. A. Eastham, H. I. Scher, V. E. Reuter, P. T. Scardino, C. Sander, C. L. Sawyers and W. L. Gerald: Integrative genomic profiling of human prostate cancer. Cancer Cell, 18(1), 11-22 (2010)

  • [43]C. S. Grasso, Y. M. Wu, D. R. Robinson, X. Cao, S. M. Dhanasekaran, A. P. Khan, M. J. Quist, X. Jing, R. J. Lonigro, J. C. Brenner, I. A. Asangani, B. Ateeq, S. Y. Chun, J. Siddiqui, L. Sam, M. Anstett, R. Mehra, J. R. Prensner, N. Palanisamy, G. A. Ryslik, F. Vandin, B. J. Raphael, L. P. Kunju, D. R. Rhodes, K. J. Pienta, A. M. Chinnaiyan and S. A. Tomlins: The mutational landscape of lethal castration-resistant prostate cancer. Nature, 487(7406), 239-243 (2012)

  • [44]P. Liu, S. Ramachandran, M. Ali Seyed, C. D. Scharer, N. Laycock, W. B. Dalton, H. Williams, S. Karanam, M. W. Datta, D. L. Jaye and C. S. Moreno: Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res, 66(8), 4011-4019 (2006)

  • [45]D. K. Vanaja, J. C. Cheville, S. J. Iturria and C. Y. Young: Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res, 63(14), 3877-3882 (2003)

  • [46]T. A. Wallace, R. L. Prueitt, M. Yi, T. M. Howe, J. W. Gillespie, H. G. Yfantis, R. M. Stephens, N. E. Caporaso, C. A. Loffredo and S. Ambs: Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res, 68(3), 927-936 (2008)

  • [47]D. R. Rhodes, J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey and A. M. Chinnaiyan: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia, 6(1), 1-6 (2004)

  • [48]G. Kristiansen: Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology, 60(1), 125-141 (2012)

  • [49]S. E. Kern: Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res, 72(23), 6097-6101 (2012)

  • [50]A. E. Rizzardi, N. K. Rosener, J. S. Koopmeiners, R. Isaksson Vogel, G. J. Metzger, C. L. Forster, L. O. Marston, J. R. Tiffany, J. B. McCarthy, E. A. Turley, C. A. Warlick, J. C. Henriksen and S. C. Schmechel: Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer, 14, 244 (2014)

  • [51]S. P. Huang, E. Levesque, C. Guillemette, C. C. Yu, C. Y. Huang, V. C. Lin, I. C. Chung, L. C. Chen, I. Laverdiere, L. Lacombe, Y. Fradet, T. Y. Chang, H. Z. Lee, S. H. Juang and B. Y. Bao: Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. Int J Cancer, 135(11), 2661-2667 (2014)

  • [52]Q. Zheng, S. B. Peskoe, J. Ribas, F. Rafiqi, T. Kudrolli, A. K. Meeker, A. M. De Marzo, E. A. Platz and S. E. Lupold: Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate, 74(16), 1655-1662 (2014)

  • [53]X. Wen, F. M. Deng and J. Wang: MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer. Am J Clin Exp Urol, 2(3), 219-230 (2014)

  • [54]A. Berlin, E. Lalonde, J. Sykes, G. Zafarana, K. C. Chu, V. R. Ramnarine, A. Ishkanian, D. H. Sendorek, I. Pasic, W. L. Lam, I. Jurisica, T. van der Kwast, M. Milosevic, P. C. Boutros and R. G. Bristow: NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. Oncotarget (2014)

  • [55]R. Mehra, Y. Shi, A. M. Udager, J. R. Prensner, A. Sahu, M. K. Iyer, J. Siddiqui, X. Cao, J. Wei, H. Jiang, F. Y. Feng and A. M. Chinnaiyan: A Novel RNA In situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer. Neoplasia, 16(12), 1121-1127 (2014)

  • [56]K. Ruenauver, R. Menon, M. A. Svensson, J. Carlsson, W. Vogel, O. Andren, M. Nowak and S. Perner: Prognostic significance of YWHAZ expression in localized prostate cancer. Prostate Cancer Prostatic Dis, 17(4), 310-314 (2014)

  • [57]T. Szarvas, S. Tschirdewahn, C. Niedworok, G. Kramer, S. Sevcenco, H. Reis, S. F. Shariat, H. Rubben and F. vom Dorp: Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. Int J Cancer, 135(7), 1596-1604 (2014)

  • [58]K. Yoshida, H. Yamazaki, S. Nakamura, K. Masui, T. Kotsuma, H. Akiyama, E. Tanaka and Y. Yoshioka: Role of novel risk classification method, Prostate Cancer Risk Index (PRIX) for clinically localized prostate cancer after high-dose-rate interstitial brachytherapy as monotherapy. Anticancer Res, 34(6), 3077-3081 (2014)

  • [59]Y. C. Wen, W. Y. Chen, W. J. Lee, S. F. Yang, L. M. Lee and M. H. Chien: Snail as a potential marker for predicting the recurrence of prostate cancer in patients at stage T2 after radical prostatectomy. Clin Chim Acta, 431, 169-173 (2014)

  • [60]J. Mendonca, A. Sharma, H. S. Kim, H. Hammers, A. Meeker, A. De Marzo, M. Carducci, M. Kauffman, S. Shacham and S. Kachhap: Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget, 5(15), 6102-6112 (2014)

  • [61]S. Y. Choi, D. Lin, P. W. Gout, C. C. Collins, Y. Xu and Y. Wang: Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev, 79-80C, 222-237 (2014)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Article

Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence

Jun Hao 1,2,4, Yan Ting Chiang 1,2,4, Peter W. Gout 1, Yuzhuo Wang 1,2,3,*
Affiliations
Article Info

1 Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, BC, Canada, V5Z 1L3

2 Vancouver Prostate Centre, Vancouver, BC, Canada, V6H 3Z6

3 Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9

4 Interdisciplinary Oncology Program, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, V5Z 1L3

*Author to whom correspondence should be addressed.

 

Abstract

Recurrence of localized prostate cancer following treatment can lead to lethal metastatic castration-resistant prostate cancer. Although numerous studies aimed at developing biomarkers for predicting recurrence of localized prostate cancer are promising, they have not yet led to useful applications. Dysregulation of exportins (XPOs, nucleocytoplasmic transporters) associated with subcellular mislocalization of proteins has been reported for various human cancers. However, most of the XPOs have not been studied in prostate cancer. In this study, we are the first to examine whether changes in expression of XPOs could be used as potential biomarkers for recurrence of localized prostate cancer. Using the oncomine database, gene expressions of 7 known XPOs by 1128 patient samples, obtained from 16 independent prostate cancer patient cohorts, were analyzed. Relatively highly elevated expression of XPO6 (compared to prostate cancer tissue) was found to be significantly associated with poor patient prognosis, in particular, with rapid recurrence in a clinical “low risk” group. As such, expression of XPO6 may be a potential prognostic biomarker for predicting prostate cancer recurrence.

Keywords

  • Prostate Cancer
  • Prognostic Biomarker
  • Cancer Recurrence
  • Exportin 6

References